News
MNKD
5.18
-2.08%
-0.11
MannKind's to advance inhaled clofazimine to phase 2/3 for lung disease after promising early data
Seeking Alpha · 01/23 11:35
MannKind's Inhaled Clofazimine Will Advance To An Adaptive Phase 2/3 Study For Potential Treatment Of Rare Lung Disease
Benzinga · 01/23 11:06
After Golden Cross, MannKind (MNKD)'s Technical Outlook is Bright
Is it a good or bad thing when a stock experiences a golden cross technical event?
Zacks · 12/06/2022 14:55
MannKind Corporation (NASDAQ:MNKD) is a favorite amongst institutional investors who own 52%
A look at the shareholders of MannKind Corporation ( NASDAQ:MNKD ) can tell us which group is most powerful. And the...
Simply Wall St. · 11/30/2022 17:29
MannKind To Rally 57%? Here Are 5 Other Price Target Changes For Wednesday
Benzinga · 11/09/2022 13:04
Tyson Foods To $61? Plus Needham Slashes PT On This Stock By 33%
Benzinga · 11/09/2022 12:34
SVB Leerink Maintains Outperform on MannKind, Raises Price Target to $6
Benzinga · 11/09/2022 11:56
--SVB Securities Adjusts Price Target on MannKind to $6 From $5, Maintains Outperform Rating
--SVB Securities Adjusts Price Target on MannKind to $6 From $5, Maintains Outperform Rating
MT Newswires · 11/09/2022 10:15
MannKind (MNKD) Reports Q3 Loss, Tops Revenue Estimates
MannKind (MNKD) delivered earnings and revenue surprises of 40% and 35.08%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/08/2022 14:15
BRIEF-Mannkind Corp Reports 2022 Third Quarter Financial Results
Reuters · 11/08/2022 13:57
MannKind Q3 EPS $(0.06) Beats $(0.09) Estimate, Sales $32.83M Beat $25.47M Estimate
Benzinga · 11/08/2022 13:02
MannKind GAAP EPS of -$0.06 beats by $0.02, revenue of $32.83M beats by $7.83M
Seekingalpha · 11/08/2022 13:02
MannKind Corporation Reports 2022 Third Quarter Financial Results
Conference Call to Begin Today at 9:00 a.m. (ET)3Q 2022 Total Revenues of $32.8 million; +48% vs. 3Q 20213Q 2022 Royalties from Tyvaso DPI of $6.2 million3Q 2022 Commercial Products Net Revenue of $16.3 million; +67% vs. 3Q 2021 DANBURY, Conn. and WESTLAKE...
GlobeNewswire · 11/08/2022 13:00
MannKind Reports Wider Loss, Rising Revenue in Q3; Shares Gain
MannKind Reports Wider Loss, Rising Revenue in Q3; Shares Gain
MT Newswires · 11/08/2022 09:50
-- Earnings Flash (MNKD) MANNKIND Posts Q3 Revenue $32.8M
-- Earnings Flash (MNKD) MANNKIND Posts Q3 Revenue $32.8M
MT Newswires · 11/08/2022 08:15
Earnings Preview: MannKind
Benzinga · 11/07/2022 14:27
MannKind Corporation to Hold 2022 Third Quarter Financial Results Conference Call on November 8, 2022
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2022 third quarter and year to date financial results and its management will host a conference call to discuss these result...
GlobeNewswire · 11/01/2022 10:00
When Can We Expect A Profit From MannKind Corporation (NASDAQ:MNKD)?
With the business potentially at an important milestone, we thought we'd take a closer look at MannKind Corporation's...
Simply Wall St. · 09/29/2022 10:13
MannKind Corporation to Participate in the Lytham Partners Fall 2022 Investor Conference
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 21, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung d...
GlobeNewswire · 09/21/2022 21:00
More
Webull provides a variety of real-time MNKD stock news. You can receive the latest news about Mannkind through multiple platforms. This information may help you make smarter investment decisions.
About MNKD
MannKind Corporation is a biopharmaceutical company. The Company is focused on the development and commercialization of inhaled therapeutic products for diabetes and orphan lung diseases, such as pulmonary arterial hypertension. The Company’s lead product is Afrezza Inhalation Powder, which is an inhaled insulin indicated to improve glycemic control in adults with diabetes. Afrezza consists of a dry powder formulation of human insulin delivered from a small portable inhaler. AFREZZA utilizes its Technosphere formulation technology. The Technosphere is a drug delivery platform that allow the oral inhalation of a range of therapeutics.